Efficacy and Safety of Osimertinib for HK Chinese with Metastatic T790M Mutated NSCLC-real world setting.

Trial Identifier: D5160R00020
Sponsor: AstraZeneca
NCTID:: NCT03219970
Start Date: September 2017
Primary Completion Date: October 2020
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Hong Kong, China